Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia.
Int J Hematol
; 89(3): 332-341, 2009 Apr.
Article
em En
| MEDLINE
| ID: mdl-19263190
ABSTRACT
A phase 1/2 study was conducted to assess the safety and efficacy of dasatinib in Japanese patients with chronic myelogenous leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph(+) ALL) resistant or intolerant to imatinib. In phase 1, 18 patients with chronic phase (CP) CML were treated with dasatinib 50, 70, or 90 mg twice daily to evaluate safety. Dasatinib
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Pirimidinas
/
Tiazóis
/
Leucemia Mieloide de Fase Crônica
/
Leucemia-Linfoma Linfoblástico de Células Precursoras
/
Antineoplásicos
Limite:
Adult
/
Aged
/
Humans
/
Middle aged
Idioma:
En
Revista:
Int J Hematol
Assunto da revista:
HEMATOLOGIA
Ano de publicação:
2009
Tipo de documento:
Article
País de afiliação:
Japão